

Contents

Preface — vii

Contributing authors — xv

List of abbreviations — xix

Valeria A. Tsvelaya, Anna Gam, Jenna Aziz and Igor R. Efimov

1 Induced pluripotent stem-cell-derived cardiomyocytes (iPSC-CMs): novel diagnostic platform — 1

- 1.1 Rationale for the emerging need for iPSC-CMs — 1
- 1.2 Cardiogenesis and iPSC differentiation — 2
- 1.3 Reprogramming limitations and improvements — 4
- 1.4 Disease modeling platform — 7
- 1.5 Drug testing platform — 9
- 1.6 Transplantation of *in vitro* derived CMs into injured areas — 11
- 1.7 Conclusion and future directions — 13
- 1.8 References — 13

Keron Navarengom, Elisa A. Ferrante, Todd E. Rasmussen and Manfred Boehm

2 Preclinical large-animal models of cardiovascular regeneration — 20

- 2.1 Introduction — 20
- 2.2 Regenerative strategies for HF — 21
- 2.3 Cardiac regeneration using PSCs — 22
- 2.4 Translational models of HF — 25
- 2.5 Large animal models — 26
 - 2.5.1 Dilated cardiomyopathy models — 26
 - 2.5.2 Surgical induction of myocardial ischemia or infarction — 28
- 2.6 Assessment of animal models — 29
- 2.7 Conclusions — 29
- 2.8 References — 29

Khawaja Husnain Haider and Muhammad Aslam

3 Cell-free therapy with stem cell secretions: protection, repair, and regeneration of the injured myocardium — 34

- 3.1 Introduction — 34
- 3.2 The secretome of each stem cell type is unique — 35
 - 3.2.1 Paracrine factors and angiogenesis — 39
 - 3.2.2 Paracrine factors and cytoprotection — 40
 - 3.2.3 Paracrine factors and immunomodulation — 42
 - 3.2.4 Paracrine factors and cell migration and homing — 44

- 3.2.5 Paracrine factors and antifibrosis — 46
- 3.3 Tempering the secretome composition with outside intervention — 48
- 3.3.1 Genetic modification of stem cells — 48
- 3.3.2 Chemical and pharmacological manipulation of cells — 51
- 3.3.3 Physical manipulation of cells — 53
- 3.3.4 Heat shock and shock wave treatment to precondition stem cells — 55
- 3.3.5 Modification of the ECM — 56
- 3.4 Conclusion and future perspective — 57
- 3.5 References — 58

Peter K. Law, Danlin M. Law, Lei Ye, Khawaja Husnain Haider, Shi Jun Song, Ping Lu, Jian-Hua Ma and Jun Ren

4 Myoblasts provide safe and effective treatments for hereditary muscular dystrophies, cardiomyopathies, type 2 diabetes, solid tumors, and aging — 71

- 4.1 Introduction — 72
- 4.2 Gene therapy in the United States — 72
- 4.3 What constitute genetic diseases? — 73
- 4.4 Two kinds of gene therapies — 73
- 4.4.1 Single gene transduction — 73
- 4.4.2 Single gene transduction deficiencies — 75
- 4.4.3 How does single gene transduction fare? — 76
- 4.5 Human genome therapy — 76
- 4.5.1 Myoblasts are not stem cells — 77
- 4.5.2 World's first human gene therapy — 78
- 4.5.3 HMGT/MTT corrects gene defects in DMD clinical trials — 78
- 4.5.4 HMGT/MTT versus Exondys 51 — 80
- 4.5.5 HMGT/MTT in heart disease clinical trials — 81
- 4.5.6 Autonomous cell injection catheter — 83
- 4.5.7 HMGT/MTT corrects gene defects in type 2 diabetes — 84
- 4.5.7.1 Human study — 84
- 4.5.7.2 Animal studies — 85
- 4.5.8 Myoblast implantation inhibits metastasis and tumor growth and induces cancer apoptosis — 87
- 4.5.9 Anti-aging aesthetica — 88
- 4.5.10 Skin cover — 89
- 4.5.11 Body sculpture — 91
- 4.5.12 Anti-aging angiomyogenesis — 92
- 4.6 Conclusion — 92
- 4.7 References — 93

S. Amer Riazuddin, Shahid Y. Khan, Muhammad Ali and John D. Gottsch

- 5 Stem cells in ophthalmology — 98**
- 5.1 Introduction — 98
 - 5.2 Cornea — 99
 - 5.2.1 Corneal epithelium — 99
 - 5.2.2 Corneal stroma — 100
 - 5.2.3 Corneal stromal stem cells — 100
 - 5.2.4 Corneal endothelium — 101
 - 5.2.5 Corneal endothelial stem cells — 101
 - 5.2.6 Conjunctiva — 102
 - 5.2.7 Conjunctival stem cells — 102
 - 5.3 Iris — 103
 - 5.3.1 IPE stem cells — 103
 - 5.4 Ciliary body — 104
 - 5.4.1 Ciliary epithelial stem cells — 104
 - 5.5 Trabecular meshwork — 104
 - 5.5.1 TM stem cells — 104
 - 5.6 Lens — 105
 - 5.6.1 Lens stem cells — 105
 - 5.7 Retina — 106
 - 5.7.1 Retinal stem cells — 106
 - 5.7.2 Retinal pigment epithelial stem cells — 106
 - 5.7.3 Retinal Müller stem cells — 106
 - 5.8 References — 107

S. Amer Riazuddin, Shahid Y. Khan, Muhammad Ali and John D. Gottsch

- 6 Stem cells for ocular therapies — 116**
- 6.1 Introduction — 116
 - 6.2 Cornea — 117
 - 6.2.1 Stem cell-based therapies for corneal epithelium — 117
 - 6.2.2 Therapeutic applications of stem cells to corneal stroma — 118
 - 6.2.3 Stem cells and corneal endothelium treatment — 118
 - 6.3 TM and stem cell therapy — 119
 - 6.4 Ocular lens and stem cell treatment — 120
 - 6.5 Stem cell-based retinal therapy — 120
 - 6.6 References — 123

Sheikh Riazuddin, Maria Tayyab Baig and Azra Mehmood

- 7 Cell therapy for liver regeneration — 130**
- 7.1 Introduction — 130
 - 7.1.1 Worldwide prevalence of liver diseases — 130
 - 7.2 Structure and function of the liver — 131

7.3	Liver diseases — 131
7.3.1	Progression of liver fibrosis to liver cirrhosis — 131
7.3.2	Liver failure — 132
7.3.3	Liver failure causes malfunctioning of other organs — 132
7.4	Conventional therapies for liver diseases — 132
7.5	Cellular therapies for liver diseases — 132
7.6	Stem cell therapy for liver diseases — 133
7.6.1	Liver stem/progenitor cells — 133
7.6.2	MSCs in the therapy of liver diseases — 134
7.6.2.1	Bone marrow-derived MSCs — 134
7.6.2.2	Adipose (tissue)-derived MSCs — 137
7.6.2.3	Umbilical-cord-tissue-derived MSCs — 138
7.6.2.4	Umbilical cord blood stem cells — 138
7.6.3	A comparison of the various sources of MSCs — 138
7.6.4	Clinical promises of MSCs — 139
7.6.5	Induced pluripotent stem cells — 139
7.7	Liver bioengineering/scaffold-assisted liver regeneration — 140
7.8	Future prospects of cellular therapies for the repair of damaged livers — 141
7.9	References — 141

Esra Cagavi, Tuba Akgul Caglar, Khawaja Husnain Haider and Gokce Ilayda Soztekin

8 Patient-specific induced pluripotent stem cells for cardiac disease modeling — 146

8.1	Introduction — 146
8.2	Methods for electrophysiological analysis — 148
8.2.1	Electrocardiogram — 149
8.2.2	Patch clamp analysis — 150
8.2.3	Multielectrode array (MEA) — 151
8.2.4	Impedance and field potential (FP) recorders — 151
8.2.5	Voltage-sensitive and Ca ²⁺ -sensitive dyes — 151
8.3	Channelopathies — 152
8.3.1	Long QT Syndrome Type-1 (LQTS-1) — 152
8.3.2	LQTS-2 — 158
8.3.3	LQTS-3 (Gain-of-Function of Na ⁺ Channel) — 161
8.3.4	Brugada syndrome — 162
8.3.5	Timothy syndrome (LQTS-8) — 163
8.3.6	LQTS-14 — 164
8.3.7	LQTS-15 — 164
8.4	Catecholaminergic polymorphic ventricular tachycardia — 165

- 8.5 Conclusion — **167**
- 8.6 References — **168**

Newton Howard, Abderrahmane Hamlat, Julie Dubourg, Mahmoud Messerer
and Eduardo Pasqualini

- 9 Role of stem cells on evolution: a hypothesis — 173**
 - 9.1 Introduction — **173**
 - 9.2 Stem cells and evolution — **174**
 - 9.3 Evolution stages — **176**
 - 9.4 Evolution and update of genetic database — **176**
 - 9.4.1 Evolution of genetic database — **176**
 - 9.4.2 Role of GSCs in genetic database update — **178**
 - 9.4.3 Memory box and update of genetic database — **179**
 - 9.5 Evolution and human emergence — **179**
 - 9.5.1 Brain evolution — **180**
 - 9.5.2 Differences between human and mammal brains — **181**
 - 9.6 Conclusions — **183**
 - 9.7 References — **183**

Index — 188

